AIM:MED

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Intelligent Ultrasound Group

Executive Summary

Intelligent Ultrasound Group plc, through its subsidiaries, develops, markets, and distributes medical training simulators in the United Kingdom, North America, and internationally. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Intelligent Ultrasound Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MED is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MED's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

0%

MED

3.4%

GB Healthcare Services

-0.3%

GB Market


1 Year Return

60.5%

MED

0.2%

GB Healthcare Services

-11.0%

GB Market

Return vs Industry: MED exceeded the UK Healthcare Services industry which returned 8.3% over the past year.

Return vs Market: MED exceeded the UK Market which returned -10% over the past year.


Shareholder returns

MEDIndustryMarket
7 Day0%3.4%-0.3%
30 Day0%16.8%10.2%
90 Day16.0%16.5%6.4%
1 Year60.5%60.5%2.1%0.2%-7.4%-11.0%
3 Year-12.9%-12.9%32.1%24.6%0.9%-11.5%
5 Year-73.9%-73.9%31.1%19.2%26.5%-2.5%

Long-Term Price Volatility Vs. Market

How volatile is Intelligent Ultrasound Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Intelligent Ultrasound Group undervalued compared to its fair value and its price relative to the market?

2.89x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MED's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MED's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MED is unprofitable, so we can't compare its PE Ratio to the XE Healthcare Services industry average.

PE vs Market: MED is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MED's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MED is good value based on its PB Ratio (2.9x) compared to the GB Healthcare Services industry average (4.7x).


Next Steps

Future Growth

How is Intelligent Ultrasound Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Intelligent Ultrasound Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Intelligent Ultrasound Group performed over the past 5 years?

-18.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MED is currently unprofitable.

Growing Profit Margin: MED is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MED is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.

Accelerating Growth: Unable to compare MED's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MED is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-14.6%).


Return on Equity

High ROE: MED has a negative Return on Equity (-28.76%), as it is currently unprofitable.


Next Steps

Financial Health

How is Intelligent Ultrasound Group's financial position?


Financial Position Analysis

Short Term Liabilities: MED's short term assets (£13.6M) exceed its short term liabilities (£1.7M).

Long Term Liabilities: MED's short term assets (£13.6M) exceed its long term liabilities (£564.0K).


Debt to Equity History and Analysis

Debt Level: MED is debt free.

Reducing Debt: MED had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MED has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MED has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 19.4% each year.


Next Steps

Dividend

What is Intelligent Ultrasound Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MED's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MED's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MED's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Stuart Gall (57 yo)

11.83yrs

Tenure

UK£245,678

Compensation

Mr. Stuart A. Gall serves as Commercial Director of Fusion IP plc. Mr. Gall serves as the Chief Executive Officer of Demasq Limited. He has been Chief Executive Officer of Intelligent Ultrasound Group plc ...


CEO Compensation Analysis

Compensation vs Market: Stuart's total compensation ($USD327.54K) is about average for companies of similar size in the UK market ($USD345.93K).

Compensation vs Earnings: Stuart's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Stuart Gall
CEO & Director11.83yrsUK£245.68k0.34%
£ 140.8k
Ian Whittaker
COO & Executive Director4.17yrsUK£167.81k0.17%
£ 68.8k
Nicholas Sleep
CTO & Directorno dataUK£222.01k0.16%
£ 64.3k
Helen Mary Jones
CFO, Director & Company Secretary0.83yrno data0.035%
£ 14.5k
Nicola Ford
Head of Marketing0.83yrno datano data
Kathryn Jenner
Head of R&D - Simulation Division2.83yrsno datano data

3.5yrs

Average Tenure

53.5yo

Average Age

Experienced Management: MED's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stuart Gall
CEO & Director11.83yrsUK£245.68k0.34%
£ 140.8k
Ian Whittaker
COO & Executive Director4.17yrsUK£167.81k0.17%
£ 68.8k
Nicholas Sleep
CTO & Directorno dataUK£222.01k0.16%
£ 64.3k
Helen Mary Jones
CFO, Director & Company Secretary0.83yrno data0.035%
£ 14.5k
Riccardo Pigliucci
Non-Executive Chairman8.83yrsUK£54.56k0.044%
£ 17.9k
David Baynes
Non-Executive Director9.83yrsUK£20.00kno data
Nicholas Avis
Independent Non-Executive Director14.83yrsUK£20.00k0.10%
£ 41.6k
Andrew Barker
Independent Non-Executive Director3.08yrsUK£20.00k0.12%
£ 48.5k
Nazar Amso
Non-Executive Medical Director & Member of Clinical Advisory Group16.83yrsUK£20.00k0.53%
£ 218.7k
Bruce Martin
Member of Clinical Advisory Groupno datano datano data
Sue Wright
Member of Clinical Advisory Groupno datano datano data
Andrew Smith
Member of Clinical Advisory Groupno datano datano data

7.7yrs

Average Tenure

58yo

Average Age

Experienced Board: MED's board of directors are considered experienced (7.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.5%.


Top Shareholders

Company Information

Intelligent Ultrasound Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Intelligent Ultrasound Group plc
  • Ticker: MED
  • Exchange: AIM
  • Founded: 2004
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: UK£41.083m
  • Shares outstanding: 269.40m
  • Website: https://www.intelligentultrasound.com

Number of Employees


Location

  • Intelligent Ultrasound Group plc
  • Hodge House
  • Floor 6A
  • Cardiff
  • South Glamorgan
  • CF10 1DY
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MEDAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPAug 2014

Biography

Intelligent Ultrasound Group plc, through its subsidiaries, develops, markets, and distributes medical training simulators in the United Kingdom, North America, and internationally. It also develops clinic...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 19:47
End of Day Share Price2020/11/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.